BridgeBio Oncology Therapeutics (BBOT) Cash & Equivalents (2024 - 2026)
BridgeBio Oncology Therapeutics (BBOT) posted Cash & Equivalents of $52.7 million for Q1 2026, down 85.91% sequentially from $373.7 million in Q4 2025, and up 5367.35% YoY from $963135.0 in Q1 2025.
BridgeBio Oncology Therapeutics (BBOT) Cash & Equivalents (2024 - 2026) Analysis & Trends
BridgeBio Oncology Therapeutics has reported Cash & Equivalents for 3 years, with the latest figure at $52.7 million in Q1 2026.
- Quarterly Cash & Equivalents rose 5367.35% year-over-year to $52.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $52.7 million (up 5367.35% YoY) and the FY2025 annual result came in at $373.7 million, up 1111.26% from the prior year.
- Cash & Equivalents slipped to $52.7 million in Q1 2026 per BBOT's latest filing, from $373.7 million in the prior quarter.
- Over five years, Cash & Equivalents peaked at $408.7 million in Q3 2025 and troughed at $664231.0 in Q2 2025.
- A 3-year average of $97.0 million and a median of $1.8 million in 2024 frame the typical range for Cash & Equivalents.
- The widest YoY moves for Cash & Equivalents: up 22790.5% in 2025, down 63.39% in 2025.
- Over 3 years, Cash & Equivalents stood at $30.9 million in 2024, then soared by 1111.26% to $373.7 million in 2025, then sank by 85.91% to $52.7 million in 2026.
- According to Business Quant data, Cash & Equivalents over the past three periods registered $52.7 million, $373.7 million, and $408.7 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash & Equiv. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 6.14 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 2.46 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 3.58 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 815.44 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 5.10 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 8.37 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 811.99 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 1.71 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 544.80 Mn |
| 10 | BridgeBio Oncology Therapeutics | 726.38 Mn | 500.67 Mn | - | 54.06 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 54.06 Mn |
| Mar 31, 2026 | 52.66 Mn |
| Dec 31, 2025 | 373.69 Mn |
| Sep 30, 2025 | 408.74 Mn |
| Jun 30, 2025 | 664,231.00 |
| Mar 31, 2025 | 963,135.00 |
| Dec 31, 2024 | 30.85 Mn |
| Sep 30, 2024 | 1.79 Mn |
| Jun 30, 2024 | 1.81 Mn |
| Mar 31, 2024 | 1.84 Mn |